Journal of the National Comprehensive Cancer Network

Article	Citations
NCCN News	1032
Intravenous Patient-Controlled Analgesia Versus Oral Opioid to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase II Trial	922
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!	657
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors	474
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Pha	425
NCCN News	357
PCL22-186: A Potential Biomarker for Radiosensitivity of Squamous Cell Carcinomas in the Head and Neck	352
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC	310
HSR24-169: Autonomic Symptoms May Suggest Paraneoplastic Neurological Syndromes in Small Cell Lung Cancer	297
HSR24-153: Real-World Clinical Outcomes of First-Line Therapies and Treatment Regimens for BRAF-Mutant Advanced/Metastatic Melanoma: Retrospective Observational Study	292
CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis	278
HSR24-127: Rectal Cancer Disparities in Age and Overall Survival Among American Indian and Alaska Native Vs Non-Hispanic White Populations	270
CLO24-055: Outcomes With Sacituzumab Govitecan in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis	263
Highlights of the NCCN Oncology Research Program	257
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care	248
My Report Card	246
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?	216
CLO23-035: Expression of PD-L1 Through Evolution Phase From Pre-Invasive to Invasive Lung Adenocarcinoma	211
HSR23-103: Pancreatic Cancer: The Impact of Early Connectivity and Coordination of Care on Retention and Time to Treat	192
CLO23-045: A Prospective Interventional Study to Assess the Response of Systemic Chemotherapy in Aggressive, Recurrent Giant Cell Tumor	159
CLO23-043: Optimal Interval Between Immune Therapy and Targeted Therapy With Sotorasib in Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer	148
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)	132
EPR24-113: The Role of Social Determinants of Health in Gastrointestinal Cancer Outcomes in the United States Context: A Systematic Review	129
HSR24-163: Comparative Assessment of Social Determinants of Health in Community and Academic Hospitals for Patients Diagnosed With Hepatocellular Carcinoma	125
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men	121

BPI25-005: Molecular Biomarker Testing Patterns and Turn-Around Time in US Patients With Advanced Non-Small Cell Lung Cancer	118
Oncology Survivorship Care Clinics: Design and Implementation of Survivorship Care Delivery Systems at NCCN Member Institutions	118
BPI25-019: Empirical Study to Estimate Real World Impact of Delay in EGFR Testing on Healthcare Resource Utilization and Cost Burden Among Early-Stage NSCLC Patients	112
BIO25-027: Addressing Early Diagnosis Challenges: Utilizing C the Signs Clinical Decision Support Platform for Pancreatic Cancer Risk Assessment	105
Hemithyroidectomy Versus Total Thyroidectomy for Sporadic Medullary Thyroid Cancer: A Chinese Nationwide Large-Scale Cohort Study	100
Highlights of the NCCN Oncology Research Program	93
Highlights of the NCCN Oncology Research Program	93
NCCN News	92
A New Administration and JNCCN	92
Statin Use During Concurrent Chemoradiotherapy for Advanced Nasopharyngeal Cancer	90
HSR24-152: Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018–2021): A Review of Criticism and Concerns in Comments From Regulators	89
EPR24-099: Clinical and Epidemiological Characterization of the Oncologic Population in a Third Level Hospital in Northeastern Mexico	77
YIA24-005: MAIT Cells are Reduced in Anorectal Mucosal Melanomas Compared to Cutaneous Melanoma GI Metastases	72
CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia	67
HSR25-181: Assessment of Content Validity of the Functional Assessment of Cancer Therapy – Cutaneous T-Cell Lymphoma (FACT-CTCL)	64
HSR25-141: Adolescent and Young Adult Cancer Patients: Our Most Financially Vulnerable Demographic	63
CLO25-078: Deciphering Risk of Early Biochemical Recurrence in Prostate Cancer Prior to Definitive Therapy	59
EPR25-128: Epidemiology of Olfactory Neuroblastoma: A SEER Stat Review	59
EPR25-138: Glioblastoma Multiforme: A SEER STAT Analysis of Epidemiological, Laterality, and Anatomical Prognostic Indicators	58
Highlights of the NCCN Oncology Research Program	57
Evaluation of NCI-Designated Cancer Center and Comprehensive Cancer Center Survivorship-Focused Websites: Information Provided and Accessibility	57
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025	54
Patient-Reported Symptom Complexity and Acute Care Utilization Among Patients With Cancer: A Population-Based Study Using a Novel Symptom Complexity Algorithm and Observational Data	51
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021	51
Cancer-Associated Venous Thromboembolic Disease, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology	51
Empowering Care Teams: Redefining Message Management to Enhance Care Delivery and Alleviate Oncologist Burnout	49
Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers	48
Advances in the Treatment of Recurrent Ovarian Cancer and Rare Malignant Ovarian Germ Cell Tumors	47
NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022	46
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology	46
QIM24-176: Technology’s Impact on Implementing the NCCN Distress Thermometer in a Community-Based Oncology Clinic	45
CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer	44
Impact of the Identification of Nonhuman Genetic Signatures in the Diagnosis and Management of Carcinoma of Unknown Primary	44
Cancer Screening and Surveillance Testing for Older Adult Cancer Survivors	43
NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High-Quality Cancer Care	43
NCCN News	43
New Treatment Options for Patients With Bladder Cancer	43
Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial	42
Out in the World Again	42
Role of Radiation Therapy in Retroperitoneal Sarcoma	40
Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy	37
CLO22-048: Treatment Outcomes of Metastatic Urothelial Cancer on Immune Checkpoint Inhibition	37
Harmonized Outcome Measures for Use in Non–Small Cell Lung Cancer Patient Registries and Clinical Practice	37
QIM23-140: Health Care Satisfaction Among Cancer Patients Undergoing Radiotherapy: A Tunisian Center Experience	37
Highlights of the NCCN Oncology Research Program	36
Optimizing BTK Inhibition in Waldenström Macroglobulinemia	36
CLO23-059: HDR-ICR Brachytherapy With Solo Anesthesia Administration as a Resource-Effective and Patient-Safe Method in Cancer Cervix	35
CLO23-032: Treatment of HER2+ Breast Cancer: A Retrospective of Disease Prognosis With Loss of HER2 Amplification on Residual Disease After Neoadjuvant Treatment in a Community Hospital Setting	33
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer	30
21-Gene Recurrence Score and Survival Outcomes in the Phase III Multicenter TAILORx Clinical Trial	30

CLO22-051: Influence of Environmental Temperature on Pathological Complete Response and Overall Survival in Breast Cancer: A National Cancer Database Population-Based Study	29
HSR25-202: Epidemiology and Outcomes of Ventricular Arrhythmias in Patients With Hypercalcemia of Malignancy: A Population-Based Study	28
Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care	28
Hope and Uncertainty in Advanced Cancers	28
EPR25-133: Frequency and Pattern of 30-Day Readmissions in Cancer Patients With C.difficile Infection	27
CRE25-044: A Case Series of Immunotherapy-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis	26
HSR25-151: EPIC Patient Portal Functionality: An Equity Analysis in Vulnerable Cancer Patients	25
HSR25-148: The State of Lung Cancer in Alabama	24
HSR25-166: Linking COVID-Related Distress and Mental Health Service Utilization Among Allogeneic Hematopoietic Stem Cell Transplant Patients	24
Impact of a Comprehensive Financial Navigation Intervention to Reduce Cancer-Related Financial Toxicity	23
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study	23
Race- and Age-Related Disparities in Cervical Cancer Mortality	22
Impact of Telemedicine on Patient Satisfaction and Perceptions of Care Quality in Radiation Oncology	22
Long-Term Tumor Stability After First-Line Treatment With Larotrectinib in an Infant With NTRK2 Fusion–Positive High-Grade Glioma	22
Urinary Circular RNA Panels to Detect HBV-Related Hepatocellular Carcinoma: A Multicenter, Large-Scale, Case-Control Study	22
Enhancing Readability of Online Patient-Facing Content: The Role of AI Chatbots in Improving Cancer Information Accessibility	21
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response	21
Diagnostic and Therapeutic Delays in Patients With Hepatocellular Carcinoma	21
QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing	20
Integrating Immune Therapies for the Treatment of Multiple Myeloma	20
CGE23-071: Real World Data on the Implementation of a Hereditary Hematological Myeloid Malignancy Workflow: Experience of a Single Academic Medical Center	20
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022	20
CLO22-086: A Phase 2, Multi-Arm Study of Anti-CD47 Antibody Magrolimab in Combination With Docetaxel in Patients With Locally Advanced or Metastatic Solid Tumors	19
NCCN News	19
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde	19
NCCN News	19
Perioperative Management of Anticoagulation and Antithrombotic Therapy	18
BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils	18
Biomarker Testing, Treatment, and Outcomes in Patients With Advanced/Metastatic Non–Small Cell Lung Cancer Using a Real-World Database	18
Machine Learning–Based Early Warning Systems for Acute Care Utilization During Systemic Therapy for Cancer	18
Updates to the Management of Patients With Relapsed or Refractory Indolent Follicular and Marginal Zone Lymphomas	18
Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer: A Potential Strategy for Systemic Therapy Deferral	18
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology	18
Priorities of Unmet Needs for Those Affected by Colorectal Cancer: Considerations From a Series of Nominal Group Technique Sessions	18
Management of Patients With Resectable and Metastatic Non–Small Cell Lung Cancer	18
Disparate Use of Chemoradiation in Elderly Patients With Localized Anal Cancer	18
NCCN News	17
HSR24-166: Implementation of an Integrated Supportive Care Medicine Consultation Service Within a Gastrointestinal Cancer Clinic: Timeliness of Referrals and Patient Access	17
Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia Among Patients With Solid Tumors	17
EPR24-101: Characteristics of Individuals With Early-Onset GI Cancers in the Southeastern US	17
Mitigating the Risk of Aberrant Use of Opioids in Patients With Cancer Pain	17
The Future of Geriatric Oncology Research: Moving Toward Interventions and Objective Biomarkers of Aging	17
HSR24-171: Utilizing Diverse Enrollment to Validate the DELFI Fragmentome Test for Advancing Lung Cancer Screening	16
Promising Practices to Reduce the Impact of Drug Shortages on Cancer Care	16
NCCN Policy Summit: Cancer Across Geography	16
Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy	15
HSR25-153: Patient Preferences and Willingness to Accept Trade-Offs for a Favorable Treatment Response Among Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	15
QIM25-228: Utilizing Patient and Provider Perspectives in Psycho-Oncology Program Development and Quality Improvement	15
First-Line PD-1 Blockade Combined With Chemotherapy for Stage IV Penile Squamous Cell Carcinoma: A Multicenter Retrospective Study	15
Changes for JNCCN in 2025	15
BIO25-026: Innovating a Digital Patient Navigation Platform (DPNP) to Help Patients With Melanoma Access Multidisciplinary Cutaneous Oncology Care	15
BIO25-024: Real-Time Clinical Trial Data Library in Non-Small Cell Lung (NSCLC), Prostate (PC), and Breast Cancer (BC) to Support Informed Treatment Decisions: Now a Reality With a Fine-Tuned Large La	15
The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL	15
Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology	15
HSR25-172: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence of Infectious Adverse Events in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Ma	15
HSR25-190: Clinical Experience With Immunotherapy in Advanced Solid Tumors – Real World Data From India	14
YIA25-001: Molecular Residual Disease (MRD) Guided Adjuvant Therapy In Renal Cell Carcinoma (RCC) - The MRD GATE RCC Study	14
HSR25-204: Clinical Characteristics and Prognosis Associated With Low PSA in Patients With De Novo Metastatic Hormone Sensitive Prostate Cancer	14
CLO25-102: Survival Outcomes in Breast Cancer Patients With Diseased Axillary Lymph Nodes: The Role of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy.	14
QIM25-230: Enhancing Communication Through Interprofessional Goal Concordant Care Training	14
Key Performance Indicators and Metrics for the Implementation of an Oral Chemotherapy Adherence Program	14
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022	13
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology	13
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022	13
Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice	13
Addressing Racial Inequity in Cancer Care: Self-Awareness Among Oncology Professionals	12
Erratum	12
EPR22-106: Decelerating Decline and Urban-Rural Differences for Gastrointestinal Cancer Mortality in the United States, 1999-2019	12
The Value and Process of Inclusion: Using Sensitive, Respectful, and Inclusive Language and Images in NCCN Content	12
Optimizing First-Line Therapy for Advanced-Stage Classic Hodgkin Lymphoma	12
CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population	12
EPR22-113: Awareness, Utilization, and NCCN Guideline-Adherence to Breast Cancer Risk Management Behavior Among a Community-Based Sample of High-Risk Women	12
Reaching Populations to Address Disparities in Cancer Care Delivery: Results From a Six-Site Initiative	12
BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic	11
HSR23-121: Assessment of Sustained MRD Negativity and Reversion in Real-World Multiple Myeloma Patients Using NGS (clonoSEQ Assay)	11
CLO23-068: Effectiveness and Toxicity of Cetuximab With Concurrent Radiotherapy in Locally Advanced Cutaneous Squamous Cell Skin Cancer: A Case Series	11
EPR22-118: Incidence of Herpes Zoster in Immunocompromised Individuals and Zoster Vaccination as an Effective Preventative Strategy	11
Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer	11
BPI23-016: Interventional Pain Management in Outpatient Setting for Cancer Patients: A Review of Literature	11
Unusual Adverse Events in a Patient With BRAF-Mutated Non–Small Cell Lung Cancer Treated With BRAF/MEK Inhibition	11

Abstracts From the NCCN 2023 Annual Conference	11
NCCN News	11
High-Risk Prevention Programs: Identifying Services for High-Risk Patients	11
EPR23-080: Oral Cancer Screening Among the Rural Indians—A Community Based Prospective Study	11
Authors’ Reply to the Letter to the Editor by Liu and Kesselheim	11
CLO23-039: Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma: A Systematic Review	11
HSR24-150: Real-World Treatment Patterns of Selumetinib Among Patients With Neurofibromatosis Type I and Plexiform Neurofibroma in the United States	10
CRE25-041: Pneumocephalus in the Setting of Endometrial Adenocarcinoma: A Case Report	10
HSR25-203: Cost-Effectiveness Evaluation of Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments Among Medicare Patients With Chronic Lymphocytic Leukemia (CLL) in First-Line (1L) and Relapsed/Refractor	10
HSR24-126: “Share the Fear”: Communication Concerns of Parents With Cancer With Dependent Children for Their Co-Parent: A Qualitative Study	10
Highlights of the NCCN Oncology Research Program	10
HSR24-148: Outcome of Positron Emission Tomography–Computed Tomography Staging in Breast Cancer Patients Having Neo-Adjuvant Systemic Therapy	10
Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults	10
CRE25-043: Treatment of HER2-Positive Breast Cancer With Leptomeningeal Metastases With Intrathecal Trastuzumab	10
Letter to the Editor: Differentiating Between Intentional Versus Unintentional Weight Loss	10
BIO22-028: Identification of Gene Expression Signature Associated With Overall Survival in Patients With Non-Small Cell Lung Cancer	10
Navigating the Challenges: Effective Management of Toxicities in CAR T-Cell Therapies	10
BPI24-010: Temporary Toilet Lids Minimize Contamination of Bathroom Surfaces With Hazardous Drugs	10
HSR24-173: Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings	10
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model	10
CLO25-080: Outcomes of Extreme Low PD-L1 Expression in Advanced Non-Small Cell Lung Cancer: Implications for Treatment Approaches	10
Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study	10
CRE24-038: Neuroendocrine Tumor of the Gallbladder: A Case Report and Literature Review.	10
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic Malignancy	9
Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma	9
Immunoglobulin Light Chain Amyloidosis: Diagnosis and Risk Assessment	9
Importance of Family History of Colorectal Carcinoma In Situ Versus Invasive Colorectal Cancer: A Nationwide Cohort Study	9
Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About	9
NCCN Guidelines for Central Nervous System Cancers: Updates in the Treatment of Adult Patients With Glioma	9
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022	9
T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy	8
Treatment Updates for Small Cell Lung Cancer	8
Aligning With the National Cancer Plan	8
NCCN News	8
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma	8
Highlights of the NCCN Oncology Research Program	8
BPI22-023: Strategies to Prevent Unplanned Emergency Department (ED) Utilization in the COVID-19 Era	8
Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair–Deficient Colorectal Cancer	8
CLO23-026: Hydrogel Slope and Optimization of Prostate-Rectal Hydrogel Placement	8
Associations Among Optimal Lung Cancer Treatment, Clinical Outcomes, and Health Care Utilization in Patients Who Underwent Comprehensive Genomic Profiling	8
CLO23-040: Electrocardiographic Findings in Cancer Patients Receiving Chemotherapy From the Colombian Coffee Triangle Region	8
HSR23-112: Disease Burden and Treatment Patterns in Patients Diagnosed With HER2- Metastatic Gastric/Gastroesophageal Junction Cancer (mG/GEJC)	8
BPI22-016: Leveraging Best Practices in Tobacco Cessation for Cancer Patients: The Fox Chase Cancer Center (FCCC) Case Study	8
Updates to Management of Multiple Myeloma	8
QIM23-133: Aligning NCCN Criteria With Testing Workflows Using a Novel Database Application (Criterion™)	8
Referral, Uptake, and Outcome of Genetic Counseling and Testing in Patients With Early-Onset Colorectal Cancer	8
Incident Cancer Detection During Multiple Waves of COVID-19: The Tsunami After the Earthquake	8
HSR23-113: Patient and Provider Perspectives on How COVID-19 Impacted Melanoma Care Delivery	8
EPR25-137: Epidemiology and Prognostication of Malignant Glomus Tumor	7
HSR25-175: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence of Venous Thromboembolism (VTE) and Immune-Related Adverse Events (iRAEs) in Patients With Primary Advanced or	7
CLO25-070: Effects and Mechanisms of CD16+/-NK Cells on Ovarian Malignant Tumor Cells Platinum-Based Drug Responsiveness in Tumor Microenvironment	7
Clinical Consequences of Altering the Definition of HER2-Positive Breast Cancer to Exclude Group 2, HER2-Negative Disease	7
BPI24-013: Microwave Ablation Versus Resection Versus Stereotactic Body Radiation Therapy of Stage IA Non–Small Cell Lung Cancer in US Veterans	7
EPR24-117: A Comprehensive Examination of Disparities in Metastatic Breast Cancer Incidence: Race, Income and Geography	7
QIM25-227: Evaluating Dosimetric Differences in Head and Neck Cancer Treatment: A RapidArc Approach With Flattening Filter-Free vs. Filtered Beams	7
Symptom Burden and Survivorship Care for Patients With Prostate Cancer on Androgen Deprivation Therapy	7
NCCN News	7
HSR25-144: Clinical Outcomes for Leukemia Patients Following Hematopoietic Stem Cell Transplant: An Analysis of the National Inpatient Sample	7
CLO25-083: Immune-Related Adverse Events in Women With Early and Advanced Triple-Negative Breast Cancer Treated With Pembrolizumab: A Multi-Center Analysis	7
Optimizing Electronic Secure Messaging to Mitigate Oncologist Burnout	7
QIM24-178: Managing Pharmaceutical Costs in the Oncology Care Model	7
HSR22-158: Managing Diabetes Mellitus During Cancer Treatment: The Missing Link to Primary Care	6
Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures	6
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024	6
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology	6
Updates in the Management of Biliary Tract Cancers	6
Advancing Health Equity in Cancer-Related Distress: Lessons Learned From the COVID-19 Pandemic on Leveraging Digital Tools and Future Directions	6
CRE24-042: Microgranular Acute Promyelocytic Leukemia Presenting as Recurrent Stroke and Isolated Neutropenia	6
Failure Doesn’t Feel Good!	6
Cardiovascular Adverse Events and Associated Costs of CDK4/6 Inhibitors in Patients With Breast Cancer	6
QIM25-223: Acceptability, Facilitators, and Barriers to the Implementation of Screening and Brief Intervention for Alcohol Counseling in the Oncology Setting	6
Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study	6
I Cannot Afford This!	6
NCCN News	6
HSR22-155: Management of Close/Positive Margins in cSCCHN	6
HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy	6
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer	6
Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series	6
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma	6
NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024	6
NCCN Guidelines® Updates: T-Cell Lymphomas	6
HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy	6
Highlights of the NCCN Oncology Research Program	5
NCCN News	5
Rurality Status and Cardiovascular Events/Survival in Older Men With Prostate Cancer	5
HSR25-168: Survival Analysis for Early Onset and Very Early Onset Colon Cancer Using National Cancer Database (NCDB) 2004-2021	5
End-of-Life Characteristics Associated With Short Hospice Length of Stay for Patients With Solid Tumors Enrolled in Phase I Clinical Trials	5
Mutational Landscape in Myeloproliferative Neoplasms: Implications on Prognosis and Clinical Management	5
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology	5
Assessing Equity in Quality Care for Metastatic Pancreatic Cancer	5
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology	5
The Prognostic Role of HPV or p16INK4a Status in Penile Squamous Cell Carcinoma: A Meta-Analysis	5
Lobbying in US Health Care—Lessons From the Field of Oncology	5
BIO22-026: Chemotherapy and Immunotherapy Infusion Reaction Documentation Standardization	5
Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking	5